These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32416115)

  • 1. Assessment of Long-term Changes in Lower Urinary Tract Symptoms in Patients With Prostate Cancer Who Underwent Low-dose-rate Prostate Brachytherapy.
    Iinuma K; Nakano M; Kato T; Kato D; Takai M; Maekawa YM; Nakane K; Mizutani K; Tsuchiya T; Ishihara T; Ito M; Matsuo M; Koie T
    Urology; 2020 Aug; 142():213-220. PubMed ID: 32416115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronological changes of lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer using SpaceOAR® system.
    Taniguchi T; Iinuma K; Nakano M; Kawase M; Takeuchi S; Kato D; Takai M; Nakane K; Ishihara T; Ito M; Kumano T; Matsuo M; Koie T
    Prostate Int; 2022 Dec; 10(4):207-212. PubMed ID: 36570644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of Clinical and Dosimetric Parameters with Urinary Toxicities after Prostate Brachytherapy: A Long-Term Single-Institution Experience.
    Ito M; Makita C; Mori T; Takano H; Kumano T; Matsuo M; Iinuma K; Kawase M; Nakane K; Nakano M; Koie T
    Curr Oncol; 2023 Jun; 30(6):5680-5689. PubMed ID: 37366909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronological Changes of Lower Urinary Tract Symptoms in Elderly Patients with Prostate Cancer after Low-Dose-Rate Prostate Brachytherapy.
    Tsuchiya K; Kawase M; Nakane K; Nakano M; Iinuma K; Kato D; Takai M; Tobisawa Y; Mori T; Takano H; Kumano T; Matsuo M; Ito T; Koie T
    Life (Basel); 2023 Jul; 13(7):. PubMed ID: 37511882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.
    Miyake M; Tanaka N; Asakawa I; Hori S; Morizawa Y; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Hasegawa M; Fujii T; Konishi N; Fujimoto K
    BMC Urol; 2017 Aug; 17(1):62. PubMed ID: 28806948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and urological toxicity of low-dose-rate brachytherapy (LDR-BT) as monotherapy in localized prostate cancer.
    Vuolukka K; Auvinen P; Palmgren JE; Voutilainen T; Aaltomaa S; Kataja V
    Brachytherapy; 2019; 18(5):583-588. PubMed ID: 31227400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
    Brousil P; Hussain M; Lynch M; Laing RW; Langley SE
    BJU Int; 2015 Apr; 115(4):580-6. PubMed ID: 24802744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factors for Resolution Delay of Lower Urinary Tract Symptoms in Patients with Prostate Cancer after Low-Dose-Rate Brachytherapy.
    Taniguchi T; Kawase M; Nakane K; Nakano M; Iinuma K; Kato D; Takai M; Tobisawa Y; Mori T; Takano H; Kumano T; Matsuo M; Ito T; Koie T
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting urinary frequency after low-dose-rate brachytherapy for prostate cancer.
    Uematsu T; Torimoto K; Tanaka N; Asakawa I; Hori S; Yamaki K; Nakai Y; Miyake M; Anai S; Hasegawa M; Fujimoto K
    Low Urin Tract Symptoms; 2022 Jan; 14(1):4-9. PubMed ID: 34288506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
    Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
    BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in patients who underwent robot-assisted radical prostatectomy compared with those who underwent low-dose-rate brachytherapy.
    Nakai Y; Tanaka N; Asakawa I; Hori S; Miyake M; Yamaki K; Anai S; Torimoto K; Inoue T; Hasegawa M; Fujimoto K
    Prostate; 2023 May; 83(7):701-712. PubMed ID: 36879383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.
    Farris JC; Hughes RT; Steber CR; Craven TE; Frizzell BA
    Brachytherapy; 2021; 20(6):1107-1113. PubMed ID: 34353749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer.
    Onishi K; Tanaka N; Miyake M; Nakai Y; Anai S; Torimoto K; Yamaki K; Asakawa I; Hasegawa M; Fujii T; Konishi N; Fujimoto K
    Clin Transl Radiat Oncol; 2019 Jan; 14():51-58. PubMed ID: 30547097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose rate brachytherapy for men with localized prostate cancer.
    Peinemann F; Grouven U; Hemkens LG; Bartel C; Borchers H; Pinkawa M; Heidenreich A; Sauerland S
    Cochrane Database Syst Rev; 2011 Jul; (7):CD008871. PubMed ID: 21735436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
    Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
    Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary symptom flare following I-125 prostate brachytherapy.
    Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
    Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
    Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR.
    Patel AK; Houser C; Benoit R; Smith RP; Beriwal S
    Brachytherapy; 2020; 19(4):477-483. PubMed ID: 32331976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
    Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.